Breaking News: Freda Biotechnology’s Natamycin Successfully Passes U.S. Drug Master File (DMF) Filing for Active Pharmaceutical Ingredients!

Recently, the U.S. Food and Drug Administration (FDA) announced on its official website that natamycin, developed independently by Freda Biotech, has successfully obtained U.S. FDA Drug Master File (DMF) certification (DMF No. 042063).

Natamycin is a polyene macrolide compound produced by Streptomyces fermentation that inhibits the growth of fungi such as molds and yeasts. In the research and manufacture of natamycin, the company has made technological innovation its central driver, deepening its expertise in critical steps and integrating the entire industrial chain. This has progressively forged a competitive edge that spans the full workflow—R&D, production, and quality control

The successful DMF filing marks another milestone in the company’s deep implementation of Freda’s strategic upgrade for raw materials, providing a “passport” to expand into high-end overseas markets and further enhancing its global competitiveness.

Going forward, the company will continue to align with the group’s overarching plan for its raw-material segment. Driven by technological innovation, it will keep unlocking the potential for broader application scenarios of its products, delivering higher-quality, more cost-effective solutions to customers worldwide.